Intervention

AGS-004

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions6

Lead sponsors shown4

Clinical trials

5 shown

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 InfectionNCT02707900 · 2016-03-01

A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004NCT02042248 · 2014-03-01

Safety and Efficacy Study of AGS-004 During Analytical Treatment InterruptionNCT01069809 · 2010-07-01

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIVNCT00672191 · 2008-02-01

A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.NCT00381212 · 2006-09-01

Common conditions

Acquired Immunodeficiency Syndrome1 HIV1 HIV Infection1 HIV Infections1 HIV Seropositivity1 HIV-1 Infection1

Leading sponsors

Argos Therapeutics2 Cynthia L Gay, MD1 McGill University Health Centre/Research Institute of the McGill University Health Centre1 University of North Carolina, Chapel Hill1

Trial status mix

COMPLETED4

TERMINATED1

Phase mix

PHASE13

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.